Creating a new generation of small molecule protease inhibitors


KalVista is advancing a pipeline of novel, small molecule plasma kallikrein inhibitors through preclinical and clinical development. We intend to develop these drug candidates as best-in-class treatments for hereditary angioedema (HAE), diabetic macular edema (DME), and other plasma kallikrein-associated diseases.

Our development programs have received grant funding from the JDRF, Innovate UK and the European Commission.

Product Portfolio

KALV pipeline January 2018

*Under Option Agreement with Merck